Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pyrotinib

pyrotinib

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer
Rheumatology Sys. Review
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer Case shows new drug combo may help breast cancer patient
This case report and literature review describes a patient with HER2+/HR+ breast cancer who achieved total pathological complete response af…
A woman with HER2-positive breast cancer achieved complete response after switching to a pyrotinib-based regimen when standard therapy faile…
Frontiers Jul 25, 2026
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
Drug Pipeline Guideline
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Frontiers Jun 21, 2026